Cairo: Minister of Industry Khaled Hashem and Minister of Investment and Foreign Trade Mohamed Farid Saleh conducted discussions with drug manufacturers and members of the Export Council for Medical Industries and Pharmaceuticals to enhance the sector's competitiveness and increase its contribution to national exports.According to State Information Service Egypt, the meeting was attended by Hossam Othman, Deputy Minister of Higher Education, along with senior officials from the Sovereign Fund of Egypt, the Egyptian Drug Authority, the Financial Regulatory Authority, and representatives of trade sectors and investment institutions. Executives from Panacea and Art Pharma were also present. This meeting aligns with the government's efforts to establish an actionable roadmap focused on localizing pharmaceutical manufacturing, deepening local content, integrating scientific research into production systems, and opening new export markets for sustainable growth.The strategy intends to solidify Egypt's position as a regional hub for medical and pharmaceutical industries. The industry minister reaffirmed his ministry's readiness to provide comprehensive support to strengthen ties between industrialists and researchers, facilitating the establishment of new pharmaceutical manufacturing projects. He emphasized the importance of adopting advanced technological solutions and artificial intelligence applications in drug development research to reduce time, cost, and effort.The government places significant importance on the pharmaceutical sector, particularly in financing and export support, to meet domestic demand while enabling expansion into international markets. The investment minister stressed that medical industries are a strategic pillar in Egypt's plan to boost exports and penetrate new markets, especially across Africa and other promising regions.The meeting reviewed a package of proposed policies aimed at accelerating sector growth, including upgrading investment incentive frameworks, strengthening financia l mechanisms to support production expansion, and fostering closer collaboration between research institutions and industrial entities. This is to speed up innovation and develop competitive medical products for global markets.